Skip to main content

Table 2 Clinical characteristics of GBM splicing types

From: Classification of glioma based on prognostic alternative splicing

 ST1(n = 49)ST2(n = 49)ST3(n = 56)Total(n = 154)
Clinical
 Age
  Median62.860.161.060.24
  No. ≤ 40 years old15612
Survival (in months)
 Median (CI)9.0 (5.47, 12.8)15.1 (13.5, 17.7)15.6 (13.5–25.5)13.8 (12.1–15.3)
Disease-free survival (in months)
 Median (CI)8.4 (6.0, NA)8.5 (6.7 13.1)11 (5.9, NA)8.5 (6.7, 13)
Karnofsky score
 10022711
 900202
 70–8019251963
  < 70861630
Sex
 Female18201654
 Male312940100
Molecular
 IDH Status
  Mutant03710
  WT464549140
 MGMT Promoter
  Methylated11172452
  Unmethylated26242171
 G-CIMP Methylation
  G-CIMP0268
  Non-G-CIMP484650144
 TERT Promoter
  Mutant491225
  WT4539414
 TERT Expression
  Expressed384247127
  Not.expressed107926
 CHR7 Gain CHR10 loss
  Gain chr7&loss chr1031323497
  No combined CNA18132051
 CHR19/20 co gain
  Gain chr19/20251219
  No chr19/20 gain474042129
Clusters
 Transcriptome Cluster
  CL492671
  MC661686
  NE51199
  PN1837261
 Original Cluster
  Classical39000
  G-CIMP7010
 IDHmut-codel012320
  IDHmut-non-codel0412767
  IDHwt049216
  Mesenchymal50000
  Neural26000
  Proneural29000
 Pan-Glioma RNA Expression Cluster
  LGr12042517
  LGr23002
  LGr39412768
  LGr412146206
 Pan-Glioma DNA Methylation Cluster
  LGm1741811
  LGm21012059
  LGm3011419
  LGm4431440
  LGm55930120
  LGm612555